VIJOINT HCC

Vijoint HCC is a patented fixed combination of Hyaluronic Acid (HA) sodium salt 2%, chondroitin-Sulfate 2% (CS) and Hydroxypropyl beta-Cyclodextrin 1%.
HA AND CS ACT IN SYNERGY TO CONTRAST DISEASE SYMPTOMS AND SLOW DOWN ITS PROGRESSION.

YOUNG TARGETHYALURONIC ACID SYSADOA: SYMPTOMATICSLOW-ACTING DRUG: improving pain, inflammation and joint function.

ELDER TARGET
CHONDROITINSULFATE DMOAD. DISEASE MODIFYING OSTEOARTHRITIS DRUG:

• Favouring subchondral bone formation
• Reducing the rate of decline in minimum joint space

Vijoint HCC, as recommended by international Guidelines, contains “pharma grade” CS of marine origin (from shark) that differs for anticoagulant, anti-inflammatory and stimulating neurite outgrowth activities, from common terrestrial sources.
Vijoint HCC is a 3D complex, formulated as HA functionalized with beta-cyclodextrin, a molecular “basket”, which hosts inside the chondroitin-sulphate and:

• overcomes the poor absorption (only 12-13%) of chondroitin taken orally
• increases the viscosity of hyaluronic acid and its loading in the joint
• protects hyaluronic acid from the enzymatic degradation of hyaluronidases

IMPROVED RESISTANCE TO THE HYALURONIDASES

Hyaluronic acid is subject to progressive degradation when in contact with hyaluronidases enzymes. Vijoint HCC, as a polymeric complex of hyaluronic acid, chondroitinsulphate and cyclodextrin, has a significantly lower enzymatic degradation rate than preparations based on hyaluronic acid only. An “in vitro” study showes the VIJOINT HCC better resistance to the hyaluronidases, expressed by a reduced formation of N-acetylexosamines terminals exposed by enzymatic “cutting action". Vijoint HCC exhibits a relevant reduction in enzymatic degradation compared to the combination of hyaluronic acid and chondroitin sulfate and not only to the solution containing sodium hyaluronate alone.